![ChromaDex Corporation](/common/images/company/N_CDXC.png)
ChromaDex Corp is a bioscience company dedicated to healthy aging. The ChromaDex team is engaged in research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. The company is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship in... ChromaDex Corp is a bioscience company dedicated to healthy aging. The ChromaDex team is engaged in research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. The company is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen. Nicotinamide riboside and other NAD+ precursors are protected by ChromaDex's patent portfolio. It delivers Niagen as the sole active ingredient in its consumer product namely, Tru Niagen which is available on Tru Niagen's website and through partnerships with retailers and distributors. Show more
ChromaDex continues to drive innovation and growth with its proprietary Tru Niagenยฎ supplement, backed by strong financial performance and a robust intellectual property portfolio ChromaDex Corp...
NR improved the six-minute walking distance and treadmill walking time for those with PAD ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research...
Clinical study results demonstrated that Niagen IV had no adverse side effects, provided superior tolerability, and a 75% shorter infusion time, with blood NAD+ levels peaking sooner and higher...
ChromaDex plans to conduct additional studies on NRC in anticipation of filing for an Investigational New Drug Application (IND) for the treatment of AT ChromaDex Corp. (NASDAQ:CDXC), the global...
ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announced today that it will be participating in Renmark Financial...
ChromaDex Corp. (NASDAQ: CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy-aging research, today announced that its Chief Executive Officer, Rob Fried, and Chief...
Judges award Niagen for its โhigh-quality, unparalleledโ healthy aging research ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging...
Total net sales of $22.2 million, gross margin of 60.7%, a net loss of $0.5 million and a positive Adjusted EBITDA of $0.7 million for the three months ended March 31, 2024. Reiterated full year...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.26 | -9.38628158845 | 2.77 | 2.7899 | 2.4414 | 251589 | 2.6294465 | CS |
4 | -0.59 | -19.0322580645 | 3.1 | 3.49 | 2.305 | 365328 | 2.86619773 | CS |
12 | -1.51 | -37.5621890547 | 4.02 | 4.19 | 2.305 | 281426 | 3.16145842 | CS |
26 | 1.01 | 67.3333333333 | 1.5 | 4.65 | 1.36 | 269596 | 3.06234165 | CS |
52 | 0.96 | 61.935483871 | 1.55 | 4.65 | 1.25 | 174756 | 2.67507046 | CS |
156 | -6.93 | -73.4110169492 | 9.44 | 10.54 | 1.15 | 276230 | 3.2270486 | CS |
260 | -1.69 | -40.2380952381 | 4.2 | 23.66 | 1.15 | 490607 | 8.34497023 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.